CVGU Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
CSPC Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.08 |
| 52 Week High | HK$3.24 |
| 52 Week Low | HK$1.92 |
| Beta | 0.68 |
| 1 Month Change | -16.80% |
| 3 Month Change | -4.59% |
| 1 Year Change | -26.76% |
| 3 Year Change | -48.01% |
| 5 Year Change | n/a |
| Change since IPO | -34.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVGU | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -0.5% |
| 1Y | -26.8% | -15.6% | 13.3% |
Return vs Industry: CVGU underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: CVGU underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| CVGU volatility | |
|---|---|
| CVGU Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: CVGU has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CVGU's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 20,300 | Cuilong Zhang | www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Limited Fundamentals Summary
| CVGU fundamental statistics | |
|---|---|
| Market cap | €6.63b |
| Earnings (TTM) | €657.49m |
| Revenue (TTM) | €3.86b |
10.1x
P/E Ratio1.7x
P/S RatioIs CVGU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVGU income statement (TTM) | |
|---|---|
| Revenue | CN¥30.27b |
| Cost of Revenue | CN¥8.90b |
| Gross Profit | CN¥21.37b |
| Other Expenses | CN¥16.21b |
| Earnings | CN¥5.16b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 70.59% |
| Net Profit Margin | 17.04% |
| Debt/Equity Ratio | 1.1% |
How did CVGU perform over the long term?
See historical performance and comparisonDividends
6.6%
Current Dividend Yield61%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 02:33 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CSPC Pharmaceutical Group Limited is covered by 51 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Sharon Shi | BOCI Research Ltd. |
| Ethan Cui | BofA Global Research |